Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dayton W. Yuen"'
Autor:
Christina M. Mingora, Bryan A. Garcia, Kevin C. Mange, Dayton W. Yuen, Monika Ciesielska, Jakko van Ingen, Patrick A. Flume, Susan E. Dorman
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-9 (2022)
Abstract Background Mycobacterial time to positivity (TTP) in liquid culture media has predictive value for longer term outcomes in pulmonary tuberculosis, but has not been thoroughly studied in nontuberculous mycobacterial pulmonary disease. This st
Externí odkaz:
https://doaj.org/article/7b1d4996b7d64463afa4fa76822397c2
Autor:
Timothy R. Aksamit, Richard J. Wallace, Dayton W. Yuen, Kozo Morimoto, Wouter Hoefsloot, David E. Griffith, Doreen Addrizzo-Harris, Kevin L. Winthrop, Kevin C. Mange, Monika Ciesielska, Rachel Thomson, Jakko van Ingen, Chris Coulter, Stephen K. Field, Patrick A. Flume, Barbara A. Brown-Elliott
Publikováno v:
Chest. 160:831-842
Background: In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobact
Autor:
Dayton W. Yuen, Nikolas J. Onufrak, Christopher M. Rubino, Jakko van Ingen, David E. Griffith, Kevin C. Mange, Kevin L. Winthrop, Sujata M. Bhavnani
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
European Journal of Drug Metabolism and Pharmacokinetics, 46, 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 2, pp. 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 277-287
European Journal of Drug Metabolism and Pharmacokinetics, 46, 2, pp. 277-287
Background and Objectives Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to
Autor:
Christina M. Mingora, Bryan A. Garcia, Kevin C. Mange, Dayton W. Yuen, Monika Ciesielska, Jakko van Ingen, Patrick A. Flume, Susan E. Dorman
Publikováno v:
BMC Infectious Diseases, 22, 1
BMC Infectious Diseases, 22
BMC Infectious Diseases, 22
Background Mycobacterial time to positivity (TTP) in liquid culture media has predictive value for longer term outcomes in pulmonary tuberculosis, but has not been thoroughly studied in nontuberculous mycobacterial pulmonary disease. This study sough
Autor:
Stephen J. Ruoss, David E. Griffith, Dayton W. Yuen, Jakko van Ingen, Kozo Morimoto, Patrick A. Flume, Kevin C. Mange, Chris Coulter, Rachel Thomson, Theodore K. Marras, Monika Ciesielska, Luigi Codecasa, Richard J. Wallace, Barbara A. Brown-Elliott, Jae-Joon Yim, Kevin L. Winthrop
Publikováno v:
Annals of the American Thoracic Society, 18, 7, pp. 1147-1157
Annals of the American Thoracic Society, 18, 1147-1157
Annals of the American Thoracic Society, 18, 1147-1157
Contains fulltext : 238192.pdf (Publisher’s version ) (Open Access) Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (AL
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a803a60eeca12a027456d42824da9e3
Autor:
David E, Griffith, Rachel, Thomson, Patrick A, Flume, Timothy R, Aksamit, Stephen K, Field, Doreen J, Addrizzo-Harris, Kozo, Morimoto, Wouter, Hoefsloot, Kevin C, Mange, Dayton W, Yuen, Monika, Ciesielska, Richard J, Wallace, Jakko, van Ingen, Barbara A, Brown-Elliott, Chris, Coulter, Kevin L, Winthrop
Publikováno v:
Chest. 160(3)
In the CONVERT study, treatment with amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) met the primary end point of increased culture conversion by month 6 in patients with treatment-refractory Mycobacterium avium
Autor:
Kevin L, Winthrop, Patrick A, Flume, Rachel, Thomson, Kevin C, Mange, Dayton W, Yuen, Monika, Ciesielska, Kozo, Morimoto, Stephen J, Ruoss, Luigi R, Codecasa, Jae-Joon, Yim, Theodore K, Marras, Jakko, van Ingen, Richard J, Wallace, Barbara A, Brown-Elliott, Chris, Coulter, David E, Griffith
Publikováno v:
Annals of the American Thoracic Society
Rationale: Patients with refractory Mycobacterium avium complex (MAC) lung disease have limited treatment options. In the CONVERT study, amikacin liposome inhalation suspension (ALIS) added to guideline-based therapy (GBT) increased culture conversio
Publikováno v:
B106. BREAKTHROUGHS IN NTM DIAGNOSIS AND TREATMENT.
Autor:
J. van Ingen, Patrick A. Flume, Chris Coulter, Dayton W. Yuen, Rachel Thomson, Sushil Pandey, Lian J. Pennings, Richard J. Wallace, David E. Griffith, Barbara A. Brown-Elliott, Melanie W. Syrmis, Kevin C. Mange, Kevin L. Winthrop
Publikováno v:
C16. NTM DISEASE - NEW DATA AND CHANGING PARADIGMS.
Autor:
Nikolas J. Onufrak, Kevin L. Winthrop, David E. Griffith, Jakko van Ingen, Dayton W. Yuen, Christopher M. Rubino, Kevin C. Mange, Sujata M. Bhavnani
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Use of parenteral amikacin to treat refractory nontuberculous mycobacterial (NTM) lung disease is limited by systemic toxicity. A population pharmacokinetic model was developed using data pooled from two randomized trials to evaluate the pharmacokine